Our group uses a multidisciplinary approach to develop new drug candidates. We apply pharmacology, molecular biology, biochemistry, computer molecular modeling and nanotechnology methods in our research. We believe that an optimal drug-development project begins with a deep understanding of molecular pharmacology and choice of a key target protein which plays an important role in the pathogenesis of a specific disease.
2013. Fellowship for participation in “ALS Drug Discovery” workshop organized by American ALS association, Washington, DC, USA.
2007. Study fellowship, EURO Science Multidisciplinary Program: Prevention and early diagnosis of metabolic syndrome, Summer school for identification of proteins and post-translation modifications by mass spectrometry, de Duve Institute, Brussels, Belgium.